Bloodstream infections in the Intensive Care Unit

Virulence

Volumn 7, Issue 3, 2016, Pages 267-279

  Bassetti, Matteo ^a,b   Righi, Elda ^a,b   Carnelutti, Alessia ^a,b  

^a Servicio de Urologia   (Italy)

^b SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

Author keywords

antimicrobial resistance; bloodstream infections; central venous catheter; combination therapy; daptomycin; de escalation; empiric therapy; intensive care unit

Indexed keywords

AMIKACIN; ANIDULAFUNGIN; BETA LACTAMASE; CARBAPENEM; CASPOFUNGIN; CEFAZOLIN; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; COLISTIN; DAPTOMYCIN; ERTAPENEM; FLUCONAZOLE; GENTAMICIN; MEROPENEM; METICILLIN; MICAFUNGIN; OXACILLIN; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ALGORITHM; BACTEREMIA; BLOODSTREAM INFECTION; CANDIDA; COMMUNITY ACQUIRED INFECTION; DRUG DOSE ESCALATION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTENSIVE CARE UNIT; LOADING DRUG DOSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; OUTCOME ASSESSMENT; PROCESS OPTIMIZATION; REVIEW; CENTRAL VENOUS CATHETER; COMBINATION DRUG THERAPY; COMMUNICABLE DISEASES; CRITICAL ILLNESS; CROSS INFECTION; DRUG EFFECTS; MICROBIOLOGY; MULTIDRUG RESISTANCE; TRANSMISSION;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CENTRAL VENOUS CATHETERS; COMMUNICABLE DISEASES; CRITICAL ILLNESS; CROSS INFECTION; DAPTOMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; INTENSIVE CARE UNITS;

EID: 84964460551     PISSN: 21505594     EISSN: 21505608     Source Type: Journal    
DOI: 10.1080/21505594.2015.1134072     Document Type: Review

References (116)

1. H.Wisplinghoff, T.Bischoff, S.M.Tallent, H.Seifert, R.P.Wenzel, M.B.Edmond. Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39(3):309-17. Epub 2004 Jul 15. Erratum in: Clin Infect Dis. 2005 Apr 1; 40(7):1077. Clin Infect Dis 2004; 39:1093
2. S.S.Magill, J.R.Edwards, W.Bamberg, Z.G.Beldavs, G.Dumyati, M.A.Kainer, R.Lynfield, M.Maloney, L.McAllister-Hollod, J.Nadle, et al. Emerging Infections Program Healthcare-Associated Infections and Antimicrobial Use Prevalence Survey Team. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 2014; 370:1198-208; PMID:24670166
3. M.Garrouste-Orgeas, J.F.Timsit, M.Tafflet, B.Misset, J.R.Zahar, L.Soufir, T.Lazard, S.Jamali, B.Mourvillier, Y.Cohen, et al. OUTCOMEREA Study Group. Excess risk of death from intensive care unit-acquired nosocomial bloodstream infections: A reappraisal. Clin Infect Dis 2006; 42:1118-26; PMID:16575729
4. J.L.Vincent, J.Rello, J.Marshall, E.Silva, A.Anzueto, C.D.Martin, R.Moreno, J.Lipman, C.Gomersall, Y.Sakr, et al. EPIC II Group of Investigators. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302:2323-9; PMID:19952319
5. J.R.Prowle, J.E.Echeverri, E.V.Ligabo, N.Sherry, G.C.Taori, T.M.Crozier, G.K.Hart, T.M.Korman, B.C.Mayall, P.D.Johnson, et al. Acquired bloodstream infection in the intensive care unit: Incidence and attributable mortality. Crit Care 2011; 15:R100; PMID:21418635
6. K.B.Laupland, D.A.Zygun, H.D.Davies, D.L.Church, T.J.Louie, C.J.Doig. Population-based assessment of intensive care unit-acquired bloodstream infections in adults: Incidence, risk factors, and associated mortality rate. Crit Care Med 2002; 30:2462-7; PMID:12441755
7. A.G.Barnett, K.Page, M.Campbell, E.Martin, R.Rashleigh-Rolls, K.Halton, D.L.Paterson, L.Hall, N.Jimmieson, K.White, et al. The increased risks of death and extra lengths of hospital and ICU stay from hospital-acquired bloodstream infections: A case-control study. BMJ Open 2013; 3:e003587; PMID:24176795
8. K.B.Laupland, H.Lee, D.B.Gregson, B.J.Manns. Cost of intensive care unit-acquired bloodstream infections. J Hosp Infect 2006; 63:124-32; PMID:16621137
9. A.Kumar, P.Ellis, Y.Arabi, D.Roberts, B.Light, J.E.Parrillo, P.Dodek, G.Wood, A.Kumar, D.Simon, et al. Cooperative Antimicrobial Therapy of Septic Shock Database Research Group. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009; 136:1237-48; PMID:19696123
10. A.Kumar, D.Roberts, K.E.Wood, B.Light, J.E.Parrillo, S.Sharma, R.Suppes, D.Feinstein, S.Zanotti, L.Taiberg, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589-96; PMID:16625125
11. J.Vallés, J.Rello, A.Ochagavía, J.Garnacho, M.A.Alcalá. Community-acquired bloodstream infection in critically ill adult patients: Impact of shock and inappropriate antibiotic therapy on survival. Chest 2003; 123:1615-24.
12. M.D.Zilberberg, A.F.Shorr, S.T.Micek, C.Vazquez-Guillamet, M.H.Kollef. Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: A retrospective cohort study. Crit Care 2014; 18:596; PMID:25412897
13. S.T.Micek, E.C.Welch, J.Khan, M.Pervez, J.A.Doherty, R.M.Reichley, J.Hoppe-Bauer, W.M.Dunne, M.H.Kollef. Resistance to empiric antimicrobial treatment predicts outcome in severe sepsis associated with Gram-negative bacteremia. J Hosp Med 2011; 6:405-10; PMID:21916003
14. K.B.Laupland, D.L.Church. Population-based epidemiology and microbiology of community-onset bloodstream infections. Clin Microbiol Rev 2014; 27:647-64; PMID:25278570
15. R.Lenz, J.R.Leal, D.L.Church, D.B.Gregson, T.Ross, K.B.Laupland. The distinct category of healthcare associated bloodstream infections. BMC Infect Dis 2012; 12:85; PMID:22487002
16. J.Vallés, F.Alvarez-Lerma, M.Palomar, A.Blanco, A.Escoresca, F.Armestar, J.M.Sirvent, C.Balasini, R.Zaragoza, M.Marín. Study Group of Infectious Diseases of the Spanish Society of Critical Care Medicine. Health-care-associated bloodstream infections at admission to the ICU. Chest 2011; 139:810-5; http://dx.doi.org/10.1378/chest.10-1715
17. K.B.Laupland, D.B.Gregson, D.A.Zygun, C.J.Doig, G.Mortis, D.L.Church. Severe bloodstream infections: A population-based assessment. Crit Care Med 2004; 32:992-7; PMID:15071391; http://dx.doi.org/10.1097/01.CCM.0000119424.31648.1E
18. K.B.Laupland, D.A.Zygun, H.D.Davies, D.L.Church, T.J.Louie, C.J.Doig. Population-based assessment of intensive care unit acquired bloodstream infections in adults: Incidence, risk factors, and associated mortality rate. Crit Care Med 2002; 30:2462-7; PMID:12441755; http://dx.doi.org/10.1097/00003246-200211000-00010
19. L.Soufir, J.F.Timsit, C.Mahe, J.Carlet, B.Regnier, S.Chevret. Attributable morbidity and mortality of catheter-related septicemia in critically ill patients: A matched, risk-adjusted, cohort study. Infect Control Hosp Epidemiol 1999; 20:396-401; PMID:10395140; http://dx.doi.org/10.1086/501639
20. R.Gahlot, C.Nigam, V.Kumar, G.Yadav, S.Anupurba. Catheter-related bloodstream infections. Int J Crit Illn Inj Sci 2014; 4:162-7; PMID:25024944; http://dx.doi.org/10.4103/2229-5151.134184
21. J.C.O'Horo, D.G.Maki, A.E.Krupp, N.Safdar. Arterial catheters as a source of bloodstream infection: A systematic review and meta-analysis. Crit Care Med 2014; 42:1334-9; PMID:24413576; http://dx.doi.org/10.1097/CCM.0000000000000166
22. A.Corona, G.Bertolini, J.Lipman, A.P.Wilson, M.Singer. Antibiotic use and impact on outcome from bacteraemic critical illness: The BActeraemia Study in Intensive Care (BASIC). J Antimicrob Chemother 2010; 65:1276-85; PMID:20335186; http://dx.doi.org/10.1093/jac/dkq088
23. S.J.Lim, J.Y.Choi, S.J.Lee, Y.J.Cho, Y.Y.Jeong, H.C.Kim, J.D.Lee, Y.S.Hwang. Intensive care unit-acquired blood stream infections: A 5-year retrospective analysis of a single tertiary care hospital in Korea. Infection 2014; 42:875-81; PMID:25030309; http://dx.doi.org/10.1007/s15010-014-0651-z
24. M.Bassetti, L.Taramasso, D.R.Giacobbe, P.Pelosi. Management of ventilator-associated pneumonia: Epidemiology, diagnosis and antimicrobial therapy. Expert Rev Anti Infect Ther 2012; 10:585-96; PMID:22702322; http://dx.doi.org/10.1586/eri.12.36
25. A.Kunac, Z.C.Sifri, A.M.Mohr, H.Horng, R.F.Lavery, D.H.Livingston. Bacteremia and ventilator-associated pneumonia: A marker for contemporaneous extra-pulmonic infection. Surg Infect (Larchmt) 2014; 15:77-83; PMID:24192306; http://dx.doi.org/10.1089/sur.2012.030
26. J.De Waele, J.Lipman, Y.Sakr, J.C.Marshall, P.Vanhems, C.Barrera Groba, M.Leone, J.L.Vincent. EPIC II Investigators. Abdominal infections in the intensive care unit: Characteristics, treatment and determinants of outcome. BMC Infect Dis. 2014; 14:420; PMID:25074742; http://dx.doi.org/10.1186/1471-2334-14-420
27. A.Tabah, D.Koulenti, K.Laupland, B.Misset, J.Valles, F.Bruzzi de Carvalho, J.A.Paiva, N.Cakar, X.Ma, P.Eggimann, et al. Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: The EUROBACT International Cohort Study. Intensive Care Med 2012 Dec; 38:1930-45; http://dx.doi.org/10.1007/s00134-012-2695-9
28. D.H.Kett, E.Azoulay, P.M.Echeverria, J.L.Vincent. Extended Prevalence of Infection in ICU Study (EPIC II) Group of Investigators. Candida bloodstream infections in intensive care units: Analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med 2011; 39:665-70; PMID:21169817; http://dx.doi.org/10.1097/CCM.0b013e318206c1ca
29. H.S.Ammerlaan, S.Harbarth, A.G.Buiting, D.W.Crook, F.Fitzpatrick, H.Hanberger, L.A.Herwaldt, P.H.van Keulen, J.A.Kluytmans, A.Kola, et al. Secular trends in nosocomial bloodstream infections: Antibiotic-resistant bacteria increase the total burden of infection. Clin Infect Dis 2013; 56:798-805; PMID:23223600; http://dx.doi.org/10.1093/cid/cis1006
30. M.E.de Kraker, P.G.Davey, H.Grundmann. BURDEN study group. Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: Estimating the burden of antibiotic resistance in Europe. PLoS Med 2011; 8:e1001104; PMID:22022233; http://dx.doi.org/10.1371/journal.pmed.1001104
31. M.Tumbarello, M.Sanguinetti, E.Montuori, E.M.Trecarichi, B.Posteraro, B.Fiori, R.Citton, T.D'Inzeo, G.Fadda, R.Cauda, et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: Importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 2007; 51:1987-94. Erratum in: Antimicrob Agents Chemother 2007; 51:3469; http://dx.doi.org/10.1128/AAC.01509-06
32. M.Bassetti, E.M.Trecarichi, A.Mesini, T.Spanu, D.R.Giacobbe, M.Rossi, E.Shenone, G.D.Pascale, M.P.Molinari, R.Cauda, et al. Risk factors and mortality of healthcare-associated and community-acquired Staphylococcus aureus bacteraemia. Clin Microbiol Infect. 2012; 18:862-9; PMID:21999245; http://dx.doi.org/10.1111/j.1469-0691.2011.03679.x
33. European Antimicrobial Resistance Surveillance Network (EARS-Net). EARSS Annual Report. 2013. Available at: http://ecdc.europa.eu/en/activities/surveillance/EARS-Net. Last access 1September2015.
34. M.Bassetti, R.De Gaudio, T.Mazzei, G.Morace, N.Petrosillo, P.Viale, G.Bello, S.La Face, M.Antonelli. A survey on infection management practices in Italian ICUs. Crit Care 2012; 16:R221; PMID:23151325; http://dx.doi.org/10.1186/cc11866
35. B.Sancak, S.Yagci, H.C.Mirza, G.Hasçelik. Evaluation of vancomycin and daptomycin MIC trends for methicillin-resistant Staphylococcus aureus blood isolates over an 11 year period. J Antimicrob Chemother 2013; 68:2689-91; PMID:23788481; http://dx.doi.org/10.1093/jac/dkt247
36. J.Kehrmann, M.Kaase, F.Szabados, S.G.Gatermann, J.Buer, P.M.Rath, J.Steinmann. Vancomycin MIC creep in MRSA blood culture isolates from Germany: a regional problem? Eur J Clin Microbiol Infect Dis 2011; 30:677-83; PMID:21229280; http://dx.doi.org/10.1007/s10096-010-1140-7
37. Vancomycin-intermediate Staphylococcus aureus (VISA), and Vancomycin-resistant Staphylococcus aureus (VRSA). 2007 Case definition. CSTE position Statement Number: 09-ID-58, 09-ID-59. Available at: http://www.cdc.gov/ncphi/disss/nndss/casedef/vancomycincurrent.htm. Last access 1September2015.
38. C.L.Moore, P.Osaki-Kiyan, N.Z.Haque, M.B.Perri, S.Donabedian, M.J.Zervos. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis 2012; 54:51-8; PMID:22109947; http://dx.doi.org/10.1093/cid/cir764
39. K.P.Murray, J.J.Zhao, S.L.Davis, R.Kullar, K.S.Kaye, P.Lephart, M.J.Rybak. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study. Clin Infect Dis 2013; 56:1562-9; PMID:23449272; http://dx.doi.org/10.1093/cid/cit112
40. C.Liu, A.Bayer, S.E.Cosgrove, R.S.Daum, S.K.Fridkin, R.J.Gorwitz, S.L.Kaplan, A.W.Karchmer, D.P.Levine, B.E.Murray, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011; 52:285-92; PMID:21217178; http://dx.doi.org/10.1093/cid/cir034
41. T.P.Lodise, N.Patel, B.M.Lomaestro, K.A.Rodvold, G.L.Drusano. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis. 2009; 49:507-14; PMID:19586413; http://dx.doi.org/10.1086/600884
42. P.N.Harris, P.A.Tambyah, D.L.Paterson. β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: Time for a reappraisal in the era of few antibiotic options? Lancet Infect Dis 2015; 15:475-85; PMID:25716293; http://dx.doi.org/10.1016/S1473-3099(14)70950-8
43. G.Dimopoulos, D.Koulenti, A.Tabah, G.Poulakou, A.Vesin, K.Arvaniti, D.Lathyris, D.K.Matthaiou, A.Armaganidis, J.F.Timsit. Bloodstream infections in ICU with increased resistance: Epidemiology and outcomes. Minerva Anestesiol 2015; 81:405-18; PMID:25220548
44. M.Tumbarello, P.Viale, C.Viscoli, E.M.Trecarichi, F.Tumietto, A.Marchese, T.Spanu, S.Ambretti, F.Ginocchio, F.Cristini, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: Importance of combination therapy. Clin Infect Dis 2012; 55:943-50; PMID:22752516; http://dx.doi.org/10.1093/cid/cis588
45. Z.A.Qureshi, D.L.Paterson, B.A.Potoski, M.C.Kilayko, G.Sandovsky, E.Sordillo,B.Polsky, J.M.Adams-Haduch, Y.Doi. Treatment outcome of bacteremia due toKPC-producing Klebsiella pneumoniae: Superiority of combination antimicrobialregimens. Antimicrob Agents Chemother 2012; 56:2108-13; PMID:22252816; http://dx.doi.org/10.1128/AAC.06268-11
46. S.G.Parisi, A.Bartolini, E.Santacatterina, E.Castellani, R.Ghirardo, A.Berto, E.Franchin, N.Menegotto, E.De Canale, T.Tommasini, et al. Prevalence of Klebsiella pneumoniae strains producing carbapenemases and increase of resistance to colistin in an Italian teaching hospital from January 2012 To December 2014. BMC Infect Dis 2015; 15:244; PMID:26116560; http://dx.doi.org/10.1186/s12879-015-0996-7
47. Y.M.Ah, A.J.Kim, J.Y.Lee. Colistin resistance in Klebsiella pneumoniae. Int J Antimicrob Agents 2014; 44:8-15; PMID:24794735; http://dx.doi.org/10.1016/j.ijantimicag.2014.02.016
48. M.Bassetti, E.Righi. SDD and colistin resistance: End of a dream? Intensive Care Med 2014; 40:1066-7; PMID:24861349; http://dx.doi.org/10.1007/s00134-014-3328-2
49. F.Kontopidou, H.Giamarellou, P.Katerelos, A.Maragos, I.Kioumis, E.Trikka-Graphakos, C.Valakis, H.C.Maltezou; Group for the Study of KPC-producing Klebsiella pneumoniae infections in intensive care units. Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: A multi-centre study on clinical outcome and therapeutic options. Clin Microbiol Infect 2014; 20:O117-23; PMID:23992130; http://dx.doi.org/10.1111/1469-0691.12341
50. Antimicrobial resistance: global report on surveillance. 2014 (WHO). Available at: http://www.who.int/drugresistance/en/. Last access 1 September 2015.
51. M.A.Pfaller, S.A.Messer, G.J.Moet, R.N.Jones, M.Castanheira. Candida bloodstream infections: Comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009). Int J Antimicrob Agents 2011; 38:65-9; PMID:21514797; http://dx.doi.org/10.1016/j.ijantimicag.2011.02.016
52. M.Bassetti, M.Merelli, E.Righi, A.Diaz-Martin, E.M.Rosello, R.Luzzati, A.Parra, E.M.Trecarichi, M.Sanguinetti, B.Posteraro, et al. Epidemiology, species distribution, antifungal susceptibility, and outcome of candidemia across five sites in Italy and Spain. J Clin Microbiol 2013; 51:4167-72; PMID:24108614; http://dx.doi.org/10.1128/JCM.01998-13
53. L.Nesher, K.V.Rolston, D.P.Shah, J.T.Tarrand, V.Mulanovich, E.J.Ariza-Heredia, R.F.Chemaly. Fecal colonization and infection with Pseudomonas aeruginosa in recipients of allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2015; 17:33-8; PMID:25546740; http://dx.doi.org/10.1111/tid.12323
54. C.von Eiff, K.Becker, K.Machka, H.Stammer, G.Peters. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med 2001; 344:11-6; PMID:11136954; http://dx.doi.org/10.1056/NEJM200101043440102
55. M.Giannella, E.M.Trecarichi, F.G.De Rosa, V.Del Bono, M.Bassetti, R.E.Lewis, A.R.Losito, S.Corcione, C.Saffioti, M.Bartoletti, et al. Risk factors for carbapenem-resistant Klebsiella pneumoniae bloodstream infection among rectal carriers: A prospective observational multicentre study. Clin Microbiol Infect 2014; 20:1357-62; PMID:24980276; http://dx.doi.org/10.1111/1469-0691.12747
56. V.Aloush, S.Navon-Venezia, Y.Seigman-Igra, S.Cabili, Y.Carmeli. Multidrug-resistant Pseudomonas aeruginosa: Risk factors and clinical impact. Antimicrob Agents Chemother 2006; 50: 43-48; PMID:16377665; http://dx.doi.org/10.1128/AAC.50.1.43-48.2006
57. P.E.Fournier, H.Richet. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006; 42:692-699; PMID:16447117; http://dx.doi.org/10.1086/500202
58. E.G.Playford, J.C.Craig, J.R.Iredell. Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: Risk factors for acquisition, infection and their consequences. J Hosp Infect 2007; 65:204-211; PMID:17254667; http://dx.doi.org/10.1016/j.jhin.2006.11.010
59. K.Hussein, H.Sprecher, T.Mashiach, I.Oren, I.Kassis, R.Finkelstein. Carbapenem resistance among Klebsiella pneumoniae isolates: Risk factors, molecular characteristics, and susceptibility patterns. Infect Control Hosp Epidemiol 2009; 30: 666-671; PMID:19496647; http://dx.doi.org/10.1086/598244
60. M.Tumbarello, E.M.Trecarichi, F.Tumietto, V.Del Bono, F.G.De Rosa, M.Bassetti, A.R.Losito, S.Tedeschi, C.Saffioti, S.Corcione, et al. Predictive models for identification of hospitalized patients harboring KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2014; 58:3514-20; PMID:24733460; http://dx.doi.org/10.1128/AAC.02373-13
61. A.A.Udy, J.A.Roberts, J.Lipman. Clinical implications of antibiotic pharmacokinetic principles in the critically ill. Intensive Care Med 2013; 39:2070-82; PMID:24045886; http://dx.doi.org/10.1007/s00134-013-3088-4
62. J.A.Roberts, S.K.Paul, M.Akova, M.Bassetti, J.J.De Waele, G.Dimopoulos, K.M.Kaukonen, D.Koulenti, C.Martin, P.Montravers, et al. DALI Study. DALI: defining antibiotic levels in intensive care unit patients: Are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 2014; 58:1072-83; PMID:24429437; http://dx.doi.org/10.1093/cid/ciu027
63. K.A.Bauer, J.E.West, J.M.O'Brien, D.A.Goff. Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections. Antimicrob Agents Chemother 2013; 57:2907-2912; PMID:23571547; http://dx.doi.org/10.1128/AAC.02365-12
64. J.M.Dulhunty, J.A.Roberts, J.S.Davis, S.A.Webb, R.Bellomo, C.Gomersall, C.Shirwadkar, G.M.Eastwood, J.Myburgh, D.L.Paterson, et al. Continuous infusion of beta-lactam antibiotics in severe sepsis: A multicenter double-blind, randomized controlled trial. Clin Infect Dis 2013; 56:236-44; PMID:23074313; http://dx.doi.org/10.1093/cid/cis856
65. T.P.LodiseJr, B.Lomaestro, G.L.Drusano. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: Clinical implications of an extended- infusion dosing strategy. Clin Infect Dis 2007; 44:357-363; PMID:17205441; http://dx.doi.org/10.1086/510590
66. M.E.Falagas, G.S.Tansarli, K.Ikawa, K.Z.Vardakas. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: A systematic review and meta-analysis. Clin Infect Dis 2013; 56:272-282.
67. F.S.Taccone, P.F.Laterre, H.Spapen, T.Dugernier, I.Delattre, B.Layeux, D.De Backer, X.Wittebole, P.Wallemacq, J.L.Vincent, F.Jacobs. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care 2010; 14:R53; PMID:20370907; http://dx.doi.org/10.1186/cc8945
68. L.Lorente, L.Lorenzo, M.M.Martín, A.Jiménez, M.L.Mora. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother 2006; 40:219-23; PMID:16449546; http://dx.doi.org/10.1345/aph.1G467
69. L.Lorente, A.Jiménez, M.M.Martín, J.L.Iribarren, J.J.Jiménez, M.L.Mora. Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion. Int J Antimicrob Agents 2009; 33:464-8; PMID:19150225; http://dx.doi.org/10.1016/j.ijantimicag.2008.10.025
70. G.W.Patel, N.Patel, A.Lat, K.Trombley, S.Enbawe, K.Manor, R.Smith, T.P.LodiseJr. Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections. Diagn Microbiol Infect Dis 2009; 64:236-40; PMID:19500529; http://dx.doi.org/10.1016/j.diagmicrobio.2009.03.002
71. M.Bassetti, E.Righi, F.Ansaldi, M.Merelli, C.Trucchi, G.De Pascale, A.Diaz-Martin, R.Luzzati, C.Rosin, L.Lagunes, et al. A multicenter study of septic shock due to candidemia: Outcomes and predictors of mortality. Intensive Care Med 2014; 40:839-45. Erratum in: Intensive Care Med 2014; 40:1186; http://dx.doi.org/10.1007/s00134-014-3310-z
72. S.Chusri, K.Silpapojakul, E.McNeil, K.Singkhamanan, V.Chongsuvivatwong. Impact of antibiotic exposure on occurrence of nosocomial carbapenem-resistant Acinetobacter baumannii infection: A case control study. J Infect Chemother 2015; 21:90-5; PMID:25454216; http://dx.doi.org/10.1016/j.jiac.2014.10.002
73. P.Marchenay, G.Blasco, J.C.Navellou, J.Leroy, P.Cholley, D.Talon, X.Bertrand, H.Gbaguidi-Haore. Acquisition of carbapenem-resistant Gram-negative bacilli in intensive care unit: Predictors and molecular epidemiology. Med Mal Infect 2015; 45:34-40; PMID:25640914; http://dx.doi.org/10.1016/j.medmal.2014.12.003
74. L.Armand-Lefèvre, C.Angebault, F.Barbier, E.Hamelet, G.Defrance, E.Ruppé, R.Bronchard, R.Lepeule, J.C.Lucet, A.El Mniai, et al.Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother 2013; 57:1488-95.V.Aloush, S.Navon-Venezia, Y.Seigman-Igra, S.Cabili, Y.Carmeli Multidrug-resistant Pseudomonas aeruginosa: Risk factors and clinical impact. Antimicrob Agents Chemother 2006; 50:43-8; http://dx.doi.org/10.1128/AAC.01823-12
75. Society for Healthcare Epidemiology of America; Infectious Diseases Society of America; Pediatric Infectious Diseases Society. Policy statement on antimicrobial stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS). Infect Control Hosp Epidemiol 2012; 33:322-7; PMID:22418625; http://dx.doi.org/10.1086/665010
76. A.L.Barry, P.C.Fuchs, S.D.Brown. In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers.Antimicrob Agents Chemother 2001; 45:1919-22; PMID:11353654; http://dx.doi.org/10.1128/AAC.45.6.1919-1922.2001
77. J.M.Streit, R.N.Jones, H.S.Sader. Daptomycin activity and spectrum: A worldwide sample of 6737 clinical Gram-positive organisms. J Antimicrob Chemother 2004; 53:669-74; PMID:14985278; http://dx.doi.org/10.1093/jac/dkh143
78. M.Bassetti, F.Ansaldi, D.De Florentiis, E.Righi, F.Pea, A.Sartor, C.Scarparo, A.Carnelutti. Is empiric daptomycin effective in reducing mortality in Staphylococcus aureus bacteraemia? A real-life experience. Intensive Care Med 2015; 41(11):2026-8
79. M.Bassetti, G.Villa, F.Ansaldi, D.De Florentiis, C.Tascini, P.Cojutti, E.Righi, A.Sartor, M.Crapis, F.G.De Rosa, et al. Risk factors associated with the onset of daptomycin non-susceptibility in Staphylococcus aureus infections in critically ill patients. Intensive Care Med 2015; 41:366-8; PMID:25447803; http://dx.doi.org/10.1007/s00134-014-3571-6
80. M.Bassetti, E.Nicco, F.Ginocchio, F.Ansaldi, D.de Florentiis, C.Viscoli. High-dose daptomycin in documented Staphylococcus aureus infections. Int J Antimicrob Agents 2010; 36:459-61; PMID:20846832; http://dx.doi.org/10.1016/j.ijantimicag.2010.07.011
81. J.Bauer, W.Siala, P.M.Tulkens, F.Van Bambeke. A combined pharmacodynamic quantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Staphylococcus aureus biofilms. Antimicrob Agents Chemother 2013; 57:2726-37; PMID:23571532; http://dx.doi.org/10.1128/AAC.00181-13
82. P.A.Moise, E.Hershberger, M.I.Amodio-Groton, K.C.Lamp. Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy. Ann Pharmacother 2009:43:1211-9; http://dx.doi.org/10.1345/aph.1M085
83. D.A.Figueroa, E.Mangini, M.Amodio-Groton, B.Vardianos, A.Melchert, C.Fana, W.Wehbeh, C.M.Urban, S.Segal-Maurer. Safety of high-dose intravenous daptomycin treatment: Three-year cumulative experience in a clinical program. Clin Infect Dis 2009; 49:177-80; PMID:19500039; http://dx.doi.org/10.1086/600039
84. R.P.Dellinger, M.M.Levy, A.Rhodes, D.Annane, H.Gerlach, S.M.Opal, J.E.Sevransky, C.L.Sprung, I.S.Douglas, et al. Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013; 39:165-228; PMID:23361625; http://dx.doi.org/10.1007/s00134-012-2769-8
85. A.Kumar, R.Zarychanski, B.Light, J.Parrillo, D.Maki, D.Simon, D.Laporta, S.Lapinsky, P.Ellis, Y.Mirzanejad, et al. Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: A propensity-matched analysis. Crit Care Med 2010; 38:1773-85; PMID:20639750; http://dx.doi.org/10.1097/CCM.0b013e3181eb3ccd
86. A.Díaz-Martín, M.L.Martínez-González, R.Ferrer, C.Ortiz-Leyba, E.Piacentini, M.J.Lopez-Pueyo, I.Martín-Loeches, M.M.Levy, A.Artigas, J.Garnacho-Montero; Edusepsis Study Group. Antibiotic prescription patterns in the empiric therapy of severe sepsis: Combination of antimicrobials with different mechanisms of action reduces mortality. Crit Care 2012; 16:R223; http://dx.doi.org/10.1186/cc11869
87. N.Safdar, J.Handelsman, D.G.Maki. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004; 4:519-27; PMID:15288826; http://dx.doi.org/10.1016/S1473-3099(04)01108-9
88. M.Paul, A.Lador, S.Grozinsky-Glasberg, L.Leibovici. Beta lactam antibioticmonotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 2014; 1:CD003344; PMID:24395715
89. J.A.Martínez, N.Cobos-Trigueros, A.Soriano, M.Almela, M.Ortega, F.Marco, C.Pitart, H.Sterzik, J.Lopez, J.Mensa. Influence of empiric therapy with a beta-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to gram-negative microorganisms. Antimicrob Agents Chemother. 2010 Sep; 54(9):3590; http://dx.doi.org/10.1128/AAC.00115-10
90. Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, Polsky B, Adams-Haduch JM, Doi Y.Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 2012; 56(4):2108-13
91. O.Zarkotou, S.Pournaras, P.Tselioti, V.Dragoumanos, V.Pitiriga, K.Ranellou, A.Prekates, K.Themeli-Digalaki, A.Tsakris. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect 2011; 17:1798-803; PMID:21595793; http://dx.doi.org/10.1111/j.1469-0691.2011.03514.x
92. G.L.Daikos, S.Tsaousi, L.S.Tzouvelekis, I.Anyfantis, M.Psichogiou, A.Argyropoulou, I.Stefanou, V.Sypsa, V.Miriagou, M.Nepka, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: Lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 2014; 58:2322-8; PMID:24514083; http://dx.doi.org/10.1128/AAC.02166-13
93. M.Tumbarello, E.M.Trecarichi, F.G.De Rosa, M.Giannella, D.R.Giacobbe, M.Bassetti, A.R.Losito, M.Bartoletti, V.Del Bono, S.Corcione, et al. ISGRI-SITA (Italian Study Group on Resistant Infections of the Società Italiana Terapia Antinfettiva). Infections caused by KPC-producing Klebsiella pneumoniae: Differences in therapy and mortality in a multicentre study. J Antimicrob Chemother. 2015; 70:2133-43; PMID:25900159; http://dx.doi.org/10.1093/jac/dkv200
94. M.Morrell, V.J.Fraser, M.H.Kollef. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: A potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49:3640-5; PMID:16127033; http://dx.doi.org/10.1128/AAC.49.9.3640-3645.2005
95. M.Cuenca-Estrella, P.E.Verweij, M.C.Arendrup, S.Arikan-Akdagli, J.Bille, J.P.Donnelly, H.E.Jensen, C.Lass-Flörl, M.D.Richardson, M.Akova, et al. ESCMID Fungal Infection Study Group. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect 2012; 18 Suppl 7:9-18; PMID:23137134; http://dx.doi.org/10.1111/1469-0691.12038
96. C.León, S.Ruiz-Santana, P.Saavedra, B.Galván, A.Blanco, C.Castro, C.Balasini, A.Utande-Vázquez, F.J.González de Molina, M.A.Blasco-Navalproto, et al. Cava Study Group. Usefulness of the “Candida score” for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: A prospective multicenter study. Crit Care Med 2009; 37:1624-33; http://dx.doi.org/10.1097/CCM.0b013e31819daa14
97. R.Bruyère, J.P.Quenot, S.Prin, F.Dalle, C.Vigneron, S.Aho, C.Leon, P.E.Charles. Empirical antifungal therapy with an echinocandin in critically-ill patients: Prospective evaluation of a pragmatic Candida score-based strategy in one medical ICU. BMC Infect Dis 2014; 14:385; http://dx.doi.org/10.1186/1471-2334-14-385
98. A.Martini, L.Gottin, N.Menestrina, V.Schweiger, D.Simion, J.L.Vincent.Procalcitonin levels in surgical patients at risk of candidemia. J Infect 2010; 60:425-30; PMID:20226210; http://dx.doi.org/10.1016/j.jinf.2010.03.003
99. O.A.Cornely, M.Bassetti, T.Calandra, J.Garbino, B.J.Kullberg, O.Lortholary, W.Meersseman, M.Akova, M.C.Arendrup, S.Arikan-Akdagli, et al. ESCMID Fungal Infection Study Group. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 2012; 18 Suppl 7:19-37; PMID:23137135; http://dx.doi.org/10.1111/1469-0691.12039
100. R.G.Masterton. Antibiotic de-escalation. Crit Care Clin 2011; 27:149-162; PMID:21144991; http://dx.doi.org/10.1016/j.ccc.2010.09.009
101. J.Garnacho-Montero, A.Gutiérrez-Pizarraya, A.Escoresca-Ortega, Y.Corcia-Palomo, E.Fernández-Delgado, I.Herrera-Melero, C.Ortiz-Leyba, J.A.Márquez-Vácaro. De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med 2014; 40:32-40; PMID:24026297; http://dx.doi.org/10.1007/s00134-013-3077-7
102. D.Mokart, G.Slehofer, J.Lambert, A.Sannini, L.Chow-Chine, J.P.Brun, P.Berger, S.Duran, M.Faucher, J.L.Blache, et al. De-escalation of antimicrobial treatment in neutropenic patients with severe sepsis: Results from an observational study. Intensive Care Med 2014; 40:41-9; PMID:24231857; http://dx.doi.org/10.1007/s00134-013-3148-9
103. M.Leone, C.Bechis, K.Baumstarck, J.Y.Lefrant, J.Albanèse, S.Jaber, A.Lepape, J.M.Constantin, L.Papazian, N.Bruder, et al. AZUREA Network Investigators. De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: A multicenter non-blinded randomized noninferiority trial. Intensive Care Med 2014; 40:1399-408; PMID:25091790; http://dx.doi.org/10.1007/s00134-014-3411-8
104. N.Daneman, K.Shore, R.Pinto, R.Fowler. Antibiotic treatment duration for bloodstream infections in critically ill patients: A national survey of Canadian infectious diseases and critical care specialists. Int J Antimicrob Agents 2011; 38:480-5; PMID:21982833; http://dx.doi.org/10.1016/j.ijantimicag.2011.07.016
105. E.Rubinstein, Y.Keynan. Short-course therapy for severe infections. Int J Antimicrob Agents 2013; 42 Suppl:S22-4; PMID:23706543; http://dx.doi.org/10.1016/j.ijantimicag.2013.04.013
106. E.Rubinstein. Short antibiotic treatment courses or how short is short? Int J Antimicrob Agents 2007; 30 Suppl 1:S76-9; PMID:17826038; http://dx.doi.org/10.1016/j.ijantimicag.2007.06.017
107. T.C.Havey, R.A.Fowler, N.Daneman. Duration of antibiotic therapy for bacteremia: A systematic review and meta-analysis. Crit Care 2011; 15:R267; PMID:22085732; http://dx.doi.org/10.1186/cc10545
108. V.De Santis, M.Gresoiu, A.Corona, A.P.Wilson, M.Singer. Bacteraemia incidence, causative organisms and resistance patterns, antibiotic strategies and outcomes in a single university hospital ICU: Continuing improvement between 2000 and 2013. J Antimicrob Chemother 2015; 70:273-8; PMID:25190722; http://dx.doi.org/10.1093/jac/dku338
109. A.Prkno, C.Wacker, F.M.Brunkhorst, P.Schlattmann. Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock–a systematic review and meta-analysis. Crit Care 2013; 17:R291; PMID:24330744; http://dx.doi.org/10.1186/cc13157
110. D.Ben-David, Y.Maor, N.Keller, G.Regev-Yochay, I.Tal, D.Shachar, A.Zlotkin, G.Smollan, G.Rahav. Potential role of active surveillance in the control of a hospital-wide outbreak of carbapenem-resistant Klebsiella pneumoniae infection. Infect Control Hosp Epidemiol 2010; 31:620-6; PMID:20370465; http://dx.doi.org/10.1086/652528
111. S.Kochar, T.Sheard, R.Sharma, A.Hui, E.Tolentino, G.Allen, D.Landman, S.Bratu, M.Augenbraun, J.Quale. Success of an infection control program to reduce the spread of carbapenem-resistant Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2009; 30:447-52; PMID:19301985; http://dx.doi.org/10.1086/596734
112. N.Gupta, B.M.Limbago, J.B.Patel, A.J.Kallen. Carbapenem-resistant Enterobacteriaceae: Epidemiology and prevention. Clin Infect Dis 2011; 53:60-7; PMID:21653305; http://dx.doi.org/10.1093/cid/cir202
113. T.I.Van der Kooi, J.C.Wille, B.H.van Benthem. Catheter application, insertion vein and length of ICU stay prior to insertion affect the risk of catheter-related bloodstream infection. J Hosp Infect 2012; 80:238-244; PMID:22243832; http://dx.doi.org/10.1016/j.jhin.2011.11.012
114. J.S.Kim, P.Holtom, C.Vigen. Reduction of catheter-related bloodstream infections through the use of a central venous line bundle: Epidemiologic and economic consequences. Am J Infect Control 2011; 39:640-646; PMID:21641088; http://dx.doi.org/10.1016/j.ajic.2010.11.005
115. K.R.Herzer, L.Niessen, D.O.Constenla, W.J.WardJr, P.J.Pronovost. Cost-effectiveness of a quality improvement programme to reduce central line-associated bloodstream infections in intensive care units in the USA. BMJ Open 2014; 4:e006065; PMID:25256190; http://dx.doi.org/10.1136/bmjopen-2014-006065
116. M.Bassetti, J.J.De Waele, P.Eggimann, J.Garnacho-Montero, G.Kahlmeter, F.Menichetti, D.P.Nicolau, J.A.Paiva, M.Tumbarello, T.Welte, et al. Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria. Intensive Care Med 2015; 41:776-95; PMID:25792203; http://dx.doi.org/10.1007/s00134-015-3719-z